Ads
related to: adpkd sensitivity criteria for prostate cancer patients- Prostate Cancer
Discover Prostate Cancer Treatments
Download our Prostate Cancer Guide
- Second Opinion
In Need of a Second Opinion?
Our Cancer Answer Line Can Help
- Need a Second Opinion?
Put Our Expertise to Work for You.
Get a Virtual Second Opinion Today.
- Prostate Cancer Treatment
Download our Prostate Cancer Guide
Find Prostate Cancer Treatments
- Prostate Cancer
Search results
Results from the WOW.Com Content Network
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common, life-threatening inherited human disorders and the most common hereditary kidney disease. [ 1 ] [ 2 ] It is associated with large interfamilial and intrafamilial variability, which can be explained to a large extent by its genetic heterogeneity and modifier genes ...
Polycystic kidney disease (ADPKD) is a life threatening hereditary disorder; it is characterized by the development of fluid-filled cyst formation and expansion of the kidney and other organs. [3] It is an autosomal dominant disease, and it is the most common hereditary disorders with a rate of occurrence of approximately 1 in 1000.
PI-RADS v2 is designed to improve detection, characterization and risk stratification in patients suspected of prostate cancer with a goal of better treatment decisions, improved outcomes and simplified reporting. However, multi-center validation trials are needed and expected to lead to modifications in the scoring system. [11]
The highest levels of acid phosphatase are found in metastasized prostate cancer. Diseases of the bone, such as Paget's disease or hyperparathyroidism , diseases of blood cells , such as sickle-cell disease or multiple myeloma or lysosomal storage diseases , such as Gaucher's disease , will show moderately increased levels.
In men with metastatic, hormone-sensitive prostate cancer, doctors may recommend adding taxane-based chemotherapy to hormone therapy. [45] This combination likely improves overall and cancer-specific survival by slowing the spread of the cancer. However, taxane-based chemotherapy may cause an increase in side effects. [45]
Biochemical recurrence is a rise in the blood level of prostate-specific antigen (PSA) in prostate cancer patients after treatment with surgery or radiation. Biochemical recurrence may occur in patients who do not have symptoms. It may mean that the cancer has come back. Also called PSA failure and biochemical relapse. [1]
Ads
related to: adpkd sensitivity criteria for prostate cancer patients